

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS II LLC  
Petitioner

v.

NPS PHARMACEUTICALS, INC.  
Patent Owner

---

Case No. IPR2015-00990 and IPR2015-01093  
Patent No. 7,056,886

---

**PETITIONER'S UPDATED EXHIBIT LIST**

EXHIBIT	DESCRIPTION	FILED
1001	Declaration of Dr. Anthony Palmieri III, Ph.D., R.Ph.	<input checked="" type="checkbox"/>
1002	CV of Dr. Palmieri	<input checked="" type="checkbox"/>
1003	U.S. Patent No. 7,056,886 to Isaacs	<input checked="" type="checkbox"/>
1004	U.S. Patent Application Ser. No. 09/750,022	<input checked="" type="checkbox"/>
1005	U.S. Patent No.5,496,801 to Holthuis <i>et al.</i>	<input checked="" type="checkbox"/>
1006	U.S. Patent No.6,120,761 to Yamazaki <i>et al.</i>	<input checked="" type="checkbox"/>
1007	March 8, 2002 Non Final Office Action	<input checked="" type="checkbox"/>
1008	June 10, 2002 Amendment and Reply	<input checked="" type="checkbox"/>
1009	February 5, 2003 Non Final Office Action	<input checked="" type="checkbox"/>
1010	July 9, 2003 Amendment and Reply	<input checked="" type="checkbox"/>
1011	September 16, 2003 Non Final Office Action	<input checked="" type="checkbox"/>
1012	March 16, 2004 Amendment and Reply	<input checked="" type="checkbox"/>
1013	June 8, 2004 Final Office Action	<input checked="" type="checkbox"/>
1014	September 7, 2004 Amendment and Reply	<input checked="" type="checkbox"/>
1015	October 4, 2004 Non Final Office Action	<input checked="" type="checkbox"/>
1016	January 4, 2005 Amendment and Reply	<input checked="" type="checkbox"/>
1017	April 4, 2005 Notice of Allowance and Fee(s) Due	<input checked="" type="checkbox"/>
1018	Kieffer & Habener, The Glucagon-Like Peptides, Endocrine Reviews 20(6): 876-913 (1999)	<input checked="" type="checkbox"/>
1019	Lomize <i>et al.</i> , Thermodynamic Model of Secondary Structure for $\alpha$ -Helical Peptides and Proteins, Biopolymers 42:239 (1997)	<input checked="" type="checkbox"/>
1020	Dacambra <i>et al.</i> , Structural Determinants for Activity of Glucagon-like Peptide-2. Biochemistry 39:8888-8894	<input checked="" type="checkbox"/>

	(July 2000)	
1021	Drucker <i>et al.</i> , Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV, Nat. Biotechnol. 15(7):673-7. (July 1997)	☒
1022	Munroe <i>et al.</i> , Prototypic G-protein coupled receptor for the intestinotrophic factor glucagon –like peptide 2, Proc. Nat'l Acad. Sci. 96:1569 (1999)	☒
1023	Drucker <i>et al.</i> , Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis, Am J. Physiology 276:G79 (1999)	☒
1024	Cleland <i>et al.</i> , Formulation and Delivery of Proteins and Peptides, American Chemical Society, Washington D.C., Chapter 1 (1994)	☒
1025	WO 99/043361 to Knudsen	☒
1026	U.S. Patent No. 4,985,244 to Makino	☒
1027	U.S. Patent No. 5,652,216 to Kornfelt <i>et al.</i>	☒
1028	PCT Publication WO98/52600	☒
1029	U.S. Patent No. 5,789,379 to Drucker <i>et al.</i>	☒
1030	Osterberg <i>et al.</i> , Physical state of L-histidine after freeze-drying and long-term storage, EP. J. of Pharm. Sci. 1999 Aug., 8:301-308.	☒
1031	<i>Intentionally Left Blank</i>	---
1032	Shire Development IPR Petition	☒
1033	Shire Federal Circuit Brief	☒
1034	Declaration of Brent Routman in Support of Petitioner's Motion for Admission <i>Pro Hac Vice</i>	☒
1035	NPS Pharmaceuticals, Inc., Annual Report (Form 10-K)	☒

	(February 18, 2015)	
1036	Declaration of Professor Marc I. Steinberg, J.D., LL.M.	<input checked="" type="checkbox"/>
1037	Joint letter from AARP, AHIP, BCBSA and PCMA to Chairmen Grassley and Goodlatte and Ranking Members Leahy and Conyers (July 9, 2015)	<input checked="" type="checkbox"/>
1038	Dean Baker, The Impact of Exempting the Pharmaceutical Industry from Patent Reviews, Center for Economic and Policy Research (July, 2015)	<input checked="" type="checkbox"/>
1039	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Gattex	<input checked="" type="checkbox"/>
1040	Matthew Herper, Inside the Pricing of a \$300,000-A-Year Drug, Forbes (January 3, 2013)	<input checked="" type="checkbox"/>